Incretin-Based Therapy for Diabetes

Incretin-based Therapy in the Management of Type 2 Diabetes

Type 2 diabetes is a progressive disease due to reduced beta cell mass, which results in the failure of traditional treatment and the need for more intensive therapeutical measures to maintain a good glycaemic control. Within the last decade there was a preoccupation for developing new classes of drugs to achieve several goals: glycaemic control, weight loss and to preserve residual beta cell m...

Integrating incretin-based therapy into type 2 diabetes management.

LEARNING OBJECTIVES 1. Explain the concept of the incretin effect and describe defects in incretin secretion and incretin action that occur in type 2 diabetes mellitus (T2DM) 2. Provide an overview of the rationale and role of incretin-based therapy as described in current practice guidelines for the management of patients with T2DM 3. Compare the efficacy, safety, and tolerability of the incre...

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

This is the second of a 2-part series focusing on newer therapies for type 2 diabetes and their cardiovascular implications. In the first segment, we reviewed the thiazolidinediones, highlighting emerging data concerning their cardiovascular effects, both positive and negative. Here, we present a corresponding discussion of the newest antihyperglycemic category, modulators of the incretin syste...

SHORT COMMENT FOR THE LANCET Challenging incretin-based therapy selection in type 2 diabetes

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?

Significant data suggest that overt hyperglycemia, either observed with or without a prior diagnosis of diabetes, contributes to an increase in mortality and morbidity in hospitalized patients. In this regard, goal-directed insulin therapy has remained as the standard of care for achieving and maintaining glycemic control in hospitalized patients with critical and noncritical illness. As such, ...